Barclays PLC Has $3.48 Million Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)

Barclays PLC boosted its stake in Keros Therapeutics, Inc. (NASDAQ:KROS) by 140.1% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 60,014 shares of the company’s stock after buying an additional 35,022 shares during the period. Barclays PLC owned approximately 0.15% of Keros Therapeutics worth $3,484,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the stock. KBC Group NV lifted its holdings in shares of Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after acquiring an additional 432 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after purchasing an additional 280 shares during the last quarter. Values First Advisors Inc. acquired a new stake in shares of Keros Therapeutics in the 3rd quarter valued at $89,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Keros Therapeutics in the 2nd quarter valued at $128,000. Finally, LMR Partners LLP bought a new position in shares of Keros Therapeutics in the 3rd quarter valued at $213,000. 71.56% of the stock is owned by institutional investors.

Keros Therapeutics Trading Up 0.5 %

NASDAQ:KROS opened at $17.12 on Tuesday. Keros Therapeutics, Inc. has a 12 month low of $15.67 and a 12 month high of $73.00. The company has a 50 day simple moving average of $54.97 and a two-hundred day simple moving average of $51.62. The company has a market cap of $693.48 million, a PE ratio of -3.29 and a beta of 1.20.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business had revenue of $0.39 million for the quarter. During the same period in the prior year, the company earned ($1.33) EPS. The company’s quarterly revenue was up 4750.0% compared to the same quarter last year. Research analysts forecast that Keros Therapeutics, Inc. will post -5.26 earnings per share for the current year.

Analyst Upgrades and Downgrades

KROS has been the subject of a number of research analyst reports. William Blair cut shares of Keros Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Thursday, December 12th. Oppenheimer dropped their price target on Keros Therapeutics from $102.00 to $63.00 and set an “outperform” rating for the company in a research note on Monday, December 16th. Cantor Fitzgerald restated an “overweight” rating on shares of Keros Therapeutics in a research report on Friday, November 22nd. Scotiabank dropped their target price on Keros Therapeutics from $77.00 to $44.00 and set a “sector outperform” rating for the company in a research report on Friday, December 13th. Finally, Truist Financial reduced their target price on shares of Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating on the stock in a report on Monday. Four research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Keros Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $75.00.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.